---
title: "Asfotase alfa - Hypophosphatasia"
sidebar: mydoc_sidebar
permalink: db09105-mesh-d007014-1.html
toc: false 
---


Path ID: `DB09105_MESH_D007014_1`
{% include image.html url="images/db09105-mesh-d007014-1.png" file="db09105-mesh-d007014-1.png" alt="db09105-mesh-d007014-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C570710 | asfotase alfa | Drug |
| MESH:C107241 | inorgainc pyrophosphate | ChemicalSubstance |
| GO:0030282 | hydroxpatite crystal growth | BiologicalProcess |
| HP:0004349 | Reduced bone mineral density | PhenotypicFeature |
| MESH:D007014 | Hypophosphatasia | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Asfotase Alfa | DECREASES ABUNDANCE OF | Inorgainc Pyrophosphate |
| Inorgainc Pyrophosphate | NEGATIVELY REGULATES | Hydroxpatite Crystal Growth |
| Hydroxpatite Crystal Growth | HAS PHENOTYPE | Reduced Bone Mineral Density |
| Reduced Bone Mineral Density | MANIFESTATION OF | Hypophosphatasia |
|---------|-----------|---------|

Reference:
  - [https://go.drugbank.com/drugs/DB09105#mechanism-of-action](https://go.drugbank.com/drugs/DB09105#mechanism-of-action){:target="_blank"}